Pleased Thanksgiving Eve from STAT reporter Andrew Joseph, filling in for the day. A observe that this text is taking a break Thursday and Friday, one thing to be grateful for certainly. Now, how you can depart you earlier than the large day? Sir Pharmalot himself recommended we make a point out of the place turkey futures stand this morning, in case anybody is making an attempt to attain a last-minute turkey at discount costs. As an alternative, we’re extra centered on gaming out our oven technique for the large meal, with a selected precedence on the pecan pie we’re on faucet for. We’re, in any case, a former winner of STAT’s pie contest, so we’ve got a popularity to uphold. A couple of extra items of knowledge as we head into the vacation: Heat up appropriately for each your turkey trots and turkey feasts — we don’t need any accidents on the market. Salads completely have a spot on the Thanksgiving desk (you want one thing brilliant and acidic to chop via the whole lot else that’s wealthy and fatty; cranberry sauce shouldn’t should shoulder that duty alone). And at last, regardless of how full you get, there’s all the time room for dessert — and sure, for an additional serving to of gratitude. Benefit from the vacation.
The U.S. Meals and Drug Administration on Tuesday accepted the primary gene remedy to deal with individuals with hemophilia B, an inherited bleeding dysfunction, STAT writes. The one-time therapy, referred to as Hemgenix, was developed by the Dutch biotech firm UniQure and shall be marketed by CSL Behring, an Australian pharmaceutical firm. Hemgenix will price $3.5 million, making it the costliest drug accepted up to now. The approval of Hemgenix gives physicians with a brand new, probably healing therapy possibility for sufferers with extreme hemophilia B, a uncommon bleeding dysfunction brought on by a genetic mutation that stops the physique from producing enough portions of a clotting protein referred to as Issue IX.